Multiple myeloma patients treated with BCMA-directed CAR T-cell therapy have high response rate
Published: 7 Dec 2019
Views: 1154
Prof Deepu Madduri - Mount Sinai, New York, USA
Prof Deepu Madduri presents data from the CARTITUDE-1 study during a press conference at the ASH 2019 meeting.
The study evaluated the response rate of JNJ-4528, a CAR-T Cell Therapy directed against B-Cell maturation antigen (BCMA), in multiple myeloma patients.
Read more about the study here.
Watch our interview with Prof Deepu Madduri here.
- Categories:
- Haematology oncology
- Antibodies & immunotherapy
Related Videos
Emerging treatments for relapsed/refractory Hodgkin’s lymphoma in China
Dr Qingqing Cai - Sun Yat-Sen University, Guangzhou, China
29 Jan 2021
Long-term follow-up of low-intensity chemotherapy with combination therapy for r...
Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA
22 Dec 2020
Real-world evidence of the use of carfilzomib among multiple myeloma patients ac...
Prof Evangelos Terpos - University of Athens, Athens, Greece
22 Dec 2020
Real-world evidence of the use of carfilzomib to refractory to lenalidomide pati...
Prof Evangelos Terpos - University of Athens, Athens, Greece
22 Dec 2020
A treatment comparison of carfilzomib, dexamethasone and daratumumab to daratumu...
Prof Evangelos Terpos - University of Athens, Athens, Greece
22 Dec 2020
ASH 2020: Immunotherapy in relapsed/refractory multiple myeloma
Dr Robert Rifkin, Prof Sagar Lonial, Prof Evangelos Terpos, Dr Nina Shah, Dr Eri...
15 Dec 2020
Clinical activity and safety of cevostamab in relapsed/refractory multiple myelo...
Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA
10 Dec 2020
Inotuzumab ozogamicin in paediatric CD22-positive r/r acute lymphoblastic leukae...
Dr Erica Brivio - Princess Máxima Center for Pediatric Oncology, Utrecht, Nether...
9 Dec 2020
MURANO: Sustained disease survival in CLL following venetoclax plus rituximab
Dr Arnon Kater - Cancer Center Amsterdam, Amsterdam, Netherlands
9 Dec 2020
